Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Minoxidil

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

ANDAs for minoxidil topical solution 5% submitted by Alpharma (75-518) and Copley Pharmaceuticals (75-619) were approved by FDA Nov. 17; Pharmacia's Rogaine Extra Strength for Men lost market exclusivity Nov. 14. Alpharma, which debuted its generic version of the hair regrowth treatment at the Private Label Manufacturers Association annual trade show in Chicago Nov. 13-14, began shipping the product Nov. 18. The 60 mL bottles will be sold in single-, double- and triple-packs and will retail for between $14.99 and $19.99 per bottle, the company says. Perrigo also plans to offer a generic version of minoxidil 5%, but was forced to push back the shipping date until April due to an unfavorable FDA inspection of its Allegan, Mich. facility (1"The Tan Sheet" Oct. 30, p. 13)

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

US FDA Developing Model Master File System To Grow Modeling, Simulation Field

US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics

Pharma’s IRA Complaints Find Sympathetic Ear In US Appeals Court But Near-Term Relief Unlikely

See All
UsernamePublicRestriction

Register

PS091939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By